Fibroblast growth factor 21: a novel biomarker for human muscle-manifesting mitochondrial disorders
- 24 April 2013
- journal article
- Published by Informa Healthcare in Expert Opinion on Medical Diagnostics
- Vol. 7 (4) , 313-317
Abstract
Diagnosis of mitochondrial disorders is challenging, because of their highly variable clinical manifestations and age-of-onset and the shortage of specific diagnostic tools. Recent molecular studies have found that serum fibroblast growth factor 21 (FGF21) has potential to be a biomarker for muscle-manifesting mitochondrial disease, as well as for follow-up of disease progression and effect of intervention. Serum FGF21 as a biomarker is compared to conventional serum diagnostic tools for mitochondrial disorders. Mitochondrial disorders are a large group of different progressive disorders, with the age-of-onset from neonatal life to late adulthood, and symptoms originating from any organ system but sharing an underlying cause of mitochondrial dysfunction. The prevalence of these disorders is about 1:2000, varying somewhat between different countries. Serum diagnostic tools include lactate, pyruvate, their ratio, creatine kinase and amino acids. However, none of these markers are both sensitive and specific. Increased levels of FGF21 cytokine were recently found in the serum of patients, who have a muscle-manifesting mitochondrial disease, thus providing a promising, novel, sensitive and specific biomarker for these disorders.Keywords
This publication has 26 references indexed in Scilit:
- FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic studyThe Lancet Neurology, 2011
- Mechanisms of mitochondrial diseasesAnnals of Medicine, 2011
- Biomarkers for mitochondrial respiratory chain disordersJournal of Inherited Metabolic Disease, 2010
- FGFs and metabolismCurrent Opinion in Pharmacology, 2009
- Thymidine kinase 2 defects can cause multi-tissue mtDNA depletion syndromeBrain, 2008
- Hepatic Fibroblast Growth Factor 21 Is Regulated by PPARα and Is a Key Mediator of Hepatic Lipid Metabolism in Ketotic StatesCell Metabolism, 2007
- Mutant mitochondrial helicase Twinkle causes multiple mtDNA deletions and a late-onset mitochondrial disease in miceProceedings of the National Academy of Sciences, 2005
- FGF-21 as a novel metabolic regulatorJournal of Clinical Investigation, 2005
- Biochemical and molecular investigations in respiratory chain deficienciesClinica Chimica Acta, 1994
- Multiple deletions of mitochondrial DNA in several tissues of a patient with severe retarded depression and familial progressive external ophthalmoplegia.Journal of Clinical Investigation, 1992